|
|
Vaccine Comparison
|
EURIFEL FeLV |
FeLV DNA vaccine gag/pol and env |
| Vaccine Information |
Vaccine Information |
- Tradename: EURIFEL FeLV
- Manufacturer: Merial
- Vaccine Ontology ID: VO_0000918
- Type: Recombinant vector vaccine
- Status: Licensed
- Host Species for Licensed Use: Cat
- Env from strain FRA
gene engineering:
- Type: Recombinant protein preparation
- Description: Canarypox-based recombinant vaccine that expresses the FeLV env and gag protective genes (Poulet et al., 2003)
- Detailed Gene Information: Click Here.
- gag
gene engineering:
- Type: Recombinant protein preparation
- Description: Canarypox-based recombinant vaccine that expresses the FeLV env and gag protective genes (Poulet et al., 2003)
- Detailed Gene Information: Click Here.
- Vector: Canarypox virus
- Immunization Route: Intramuscular injection (i.m.)
- Description: Canarypox virus-vectored vaccine
|
- Vaccine Ontology ID: VO_0004492
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Kitten
- env from FeLV-A/Glasgow
gene engineering:
- Type: DNA vaccine construction
- Description: Vector pUSE1 expressed two separate pUSE12 series constructs, one expressing FeLV gag/pol genes and the other expressing the FeLV subgroup A env gene (Hanlon et al., 2001).
- Detailed Gene Information: Click Here.
- Vector: pUSE1- is a mammalian expression vector derived from the vector pCI-neo (Promega) (Hanlon et al., 2001)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
Host Response |
|
Cat Response
- Challenge Protocol: Oronasal FeLV challenge
- Efficacy: The vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge (Poulet et al., 2003).
|
Cat Response
- Vaccine Immune Response Type: VO_0000286
- Efficacy: The vaccine consisting of FeLV DNA with the IL-12 and IL-18 genes conferred significant immunity, protecting completely against transient and persistent viremia, and in five of six kittens protecting against latent infection (Hanlon et al., 2001).
|
| References |
References |
Poulet et al., 2003: Poulet H, Brunet S, Boularand C, Guiot AL, Leroy V, Tartaglia J, Minke J, Audonnet JC, Desmettre P. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. The Veterinary record. 2003; 153(5); 141-145. [PubMed: 12934796].
|
Hanlon et al., 2001: Hanlon L, Argyle D, Bain D, Nicolson L, Dunham S, Golder MC, McDonald M, McGillivray C, Jarrett O, Neil JC, Onions DE. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. Journal of virology. 2001; 75(18); 8424-8433. [PubMed: 11507187].
|
|
